<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210406050864N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-07</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of intravenous metoclopramide on gastric emptying</public_title>
      <acronym>ندارد</acronym>
      <scientific_title>Evaluation of the effect of intravenous metoclopramide on gastric emptying in drug-using patients based on ultrasound criteria</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>135</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57465</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study, participants and the clinical caregiver who is the assistant in charge of the patient will be fully aware of the type of prescription. But the researcher himself, as well as the outcome assessor and data analyst, will be unaware of prescribing to the groups.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Effect of methoclopramide on gastric motility.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: will include patients taking opium with a BMI less than 35. Who have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. After obtaining full consent and explanations on how to implement the plan, these patients will be included in the study and will be monitored and recorded at baseline values. These patients undergo ultrasound in both supine and right lateral position (RLP). After recording the measurements, 10 mg (2 cc) of metoclopramide is administered intravenously to patients. The ultrasound is then repeated 30 minutes later and these measurements will be recorded again. Ultrasound is used to qualitatively examine the material and contents of the stomach (liquid or solid). And antral-gastric grade are classified into three grades: zero, one and two:                                                              GRADE 0=absence of fluid                                                                      GRADE 1 = fluid in RLP position                                                                                 GRAD 2=fluid in both supine and RLP position                                                Quantitative examination will be in the form of Antral cross-sectional area (ACS) and Antral volume measurements. CSA will be calculated by measuring the vertical thickness in the two longitudinal (d1) and anterior-posterior planes (from serosa to serosa) (d2) and using the formula    CSA = 3.14 (d1 * d2) 4%.                                                                             This mathematical model is used to calculate the volume of stomach contents and determine the volume.                                                  VOLUME = 27 + (14.6 × RL CSA) _ (1.28 × age). Intervention 2: Control group:  will include non-opium user patients with a BMI less than 35. Who have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. And all the interventions performed for intervention group 1 will be performed in the control group. Intervention 3: Control group 2: will include non-opium user patients with a BMI less than 35. Have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. Have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. All interventions in this group will be similar to the intervention group, but instead of administering metoclopramide, 2 ml of distilled water will be injected intravenously (placebo) for these patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Disagreement of some study participants with sharing of their information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohamad javad Yazdipoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madani St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>+98 21 7443 2380</telephone>
        <email>Mjyazdipooor@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohamad javad Yazdipoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madani St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>98 73432380</telephone>
        <email>Mjyazdipooor@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients referred to the emergency department between the age of 16 and 80years
All patients referred to the emergency department with BMI less than 35
All patients referred to the emergency department with history of opium use
All patients who had consumed solid food in the past 8 hours or liquids in the previous 2 hours in the intervention group</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who are unable to have an ultrasound for any reason
Patients with a history of diabetes
Patients with a history of gastrointestinal surgery
Patients with suspected gastrointestinal obstruction
Patients taking medication that affects gastrointestinal motility
Patients with a history of inflammatory bowel disease
Patients with a history of irritable bowel disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: will include patients taking opium with a BMI less than 35. Who have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. After obtaining full consent and explanations on how to implement the plan, these patients will be included in the study and will be monitored and recorded at baseline values. These patients undergo ultrasound in both supine and right lateral position (RLP). After recording the measurements, 10 mg (2 cc) of metoclopramide is administered intravenously to patients. The ultrasound is then repeated 30 minutes later and these measurements will be recorded again. Ultrasound is used to qualitatively examine the material and contents of the stomach (liquid or solid). And antral-gastric grade are classified into three grades: zero, one and two:                                                              GRADE 0=absence of fluid                                                                      GRADE 1 = fluid in RLP position                                                                                 GRAD 2=fluid in both supine and RLP position                                                Quantitative examination will be in the form of Antral cross-sectional area (ACS) and Antral volume measurements. CSA will be calculated by measuring the vertical thickness in the two longitudinal (d1) and anterior-posterior planes (from serosa to serosa) (d2) and using the formula    CSA = 3.14 (d1 * d2) 4%.                                                                             This mathematical model is used to calculate the volume of stomach contents and determine the volume.                                                  VOLUME = 27 + (14.6 × RL CSA) _ (1.28 × age)</i_keyword>
      <i_keyword>Control group:  will include non-opium user patients with a BMI less than 35. Who have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. And all the interventions performed for intervention group 1 will be performed in the control group.</i_keyword>
      <i_keyword>Control group 2: will include non-opium user patients with a BMI less than 35. Have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. Have consumed solid food in the last 8 hours or consumed clear liquids in the last 2 hours. All interventions in this group will be similar to the intervention group, but instead of administering metoclopramide, 2 ml of distilled water will be injected intravenously (placebo) for these patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Gastric emptying. Timepoint: 30min. Method of measurement: sonographic criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-30</approval_date>
        <contact_name>Ethics comitte of shahid beheshti university of medical science</contact_name>
        <contact_address>Yaman Street tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
